TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $4.43 billion. The enterprise value is $4.34 billion.
Important Dates
The next estimated earnings date is Monday, March 3, 2025, before market open.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 143.52 million shares outstanding. The number of shares has increased by 3.08% in one year.
| Current Share Class | 143.52M |
| Shares Outstanding | 143.52M |
| Shares Change (YoY) | +3.08% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 7.45% |
| Owned by Institutions (%) | 71.33% |
| Float | 132.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 46.60 |
| PS Ratio | 16.88 |
| Forward PS | 8.56 |
| PB Ratio | 23.08 |
| P/TBV Ratio | 23.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.40 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.59, with a Debt / Equity ratio of 1.32.
| Current Ratio | 4.59 |
| Quick Ratio | 3.65 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | 136.31 |
| Debt / FCF | n/a |
| Interest Coverage | -0.03 |
Financial Efficiency
Return on equity (ROE) is -8.05% and return on invested capital (ROIC) is -0.09%.
| Return on Equity (ROE) | -8.05% |
| Return on Assets (ROA) | -0.07% |
| Return on Invested Capital (ROIC) | -0.09% |
| Return on Capital Employed (ROCE) | -0.11% |
| Revenue Per Employee | $1.00M |
| Profits Per Employee | -$54,409 |
| Employee Count | 264 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 0.52 |
Taxes
In the past 12 months, TG Therapeutics has paid $479,000 in taxes.
| Income Tax | 479,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +133.41% in the last 52 weeks. The beta is 2.26, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.26 |
| 52-Week Price Change | +133.41% |
| 50-Day Moving Average | 31.22 |
| 200-Day Moving Average | 24.63 |
| Relative Strength Index (RSI) | 46.88 |
| Average Volume (20 Days) | 1,714,955 |
Short Selling Information
The latest short interest is 26.88 million, so 18.73% of the outstanding shares have been sold short.
| Short Interest | 26.88M |
| Short Previous Month | 27.63M |
| Short % of Shares Out | 18.73% |
| Short % of Float | 20.25% |
| Short Ratio (days to cover) | 10.16 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $264.79 million and -$14.36 million in losses. Loss per share was -$0.10.
| Revenue | 264.79M |
| Gross Profit | 233.85M |
| Operating Income | -505,000 |
| Pretax Income | 95.78M |
| Net Income | -14.36M |
| EBITDA | -408,000 |
| EBIT | -505,000 |
| Loss Per Share | -$0.10 |
Full Income StatementBalance Sheet
The company has $341.04 million in cash and $253.81 million in debt, giving a net cash position of $87.23 million or $0.61 per share.
| Cash & Cash Equivalents | 341.04M |
| Total Debt | 253.81M |
| Net Cash | 87.23M |
| Net Cash Per Share | $0.61 |
| Equity (Book Value) | 192.16M |
| Book Value Per Share | 1.34 |
| Working Capital | 448.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.09 million and capital expenditures -$24,000, giving a free cash flow of -$28.11 million.
| Operating Cash Flow | -28.09M |
| Capital Expenditures | -24,000 |
| Free Cash Flow | -28.11M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is 88.31%, with operating and profit margins of -0.19% and -5.42%.
| Gross Margin | 88.31% |
| Operating Margin | -0.19% |
| Pretax Margin | -5.24% |
| Profit Margin | -5.42% |
| EBITDA Margin | -0.15% |
| EBIT Margin | -0.19% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.08% |
| Shareholder Yield | -3.08% |
| Earnings Yield | -0.32% |
| FCF Yield | -0.63% |
Dividend DetailsAnalyst Forecast
The average price target for TG Therapeutics is $40.67, which is 31.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.67 |
| Price Target Difference | 31.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 38.37% |
| EPS Growth Forecast (5Y) | 90.33% |
Stock ForecastsStock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 0.0177777:1.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.0177777:1 |
Scores
TG Therapeutics has an Altman Z-Score of 1.23. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.23 |
| Piotroski F-Score | n/a |